NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression

FDA-compliant manufacture of intravenous Ketamine is a required component of a New Drug Application Intravenous Ketamine has become widely used for treating depression and suicidality but has never been presented to FDA for approval Potential to file New Drug Application for Ketamine in…